369 related articles for article (PubMed ID: 33044735)
1. Direct oral anticoagulants versus vitamin K antagonists in patients with atrial fibrillation and cancer a meta-analysis.
Mariani MV; Magnocavallo M; Straito M; Piro A; Severino P; Iannucci G; Chimenti C; Mancone M; Rocca DGD; Forleo GB; Fedele F; Lavalle C
J Thromb Thrombolysis; 2021 Feb; 51(2):419-429. PubMed ID: 33044735
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of direct oral anticoagulants vs vitamin K antagonists in patients with atrial fibrillation and end-stage renal disease on hemodialysis: A systematic review and meta-analysis.
Kyriakoulis I; Adamou A; Stamatiou I; Chlorogiannis DD; Kardoutsos I; Koukousaki D; Ntaios G
Eur J Intern Med; 2024 Jan; 119():45-52. PubMed ID: 37648582
[TBL] [Abstract][Full Text] [Related]
3. Direct Oral Anticoagulants Versus Vitamin-K Antagonist After PCIs in Patients With AF: A Meta-analysis of Cardiac Ischemic Events.
Cordero A; Ferreiro JL; Bertomeu-González V; Rodríguez-Mañero M; Fácila L; Escribano D; Sanchez-Recalde A; Zuazola P; Ruiz-Nodar JM; González-Juanatey JR
J Cardiovasc Pharmacol; 2021 Feb; 77(2):164-169. PubMed ID: 33351537
[TBL] [Abstract][Full Text] [Related]
4. Clinical Benefit of Direct Oral Anticoagulants Versus Vitamin K Antagonists in Patients with Atrial Fibrillation and Bioprosthetic Heart Valves.
Russo V; Carbone A; Attena E; Rago A; Mazzone C; Proietti R; Parisi V; Scotti A; Nigro G; Golino P; D'Onofrio A
Clin Ther; 2019 Dec; 41(12):2549-2557. PubMed ID: 31735436
[TBL] [Abstract][Full Text] [Related]
5. An Evidence-Based Approach to Anticoagulation Therapy Comparing Direct Oral Anticoagulants and Vitamin K Antagonists in Patients With Atrial Fibrillation and Bioprosthetic Valves: A Systematic Review, Meta-Analysis, and Network Meta-Analysis.
Suppah M; Kamal A; Saadoun R; Baradeiya AMA; Abraham B; Alsidawi S; Sorajja D; Fortuin FD; Arsanjani R
Am J Cardiol; 2023 Nov; 206():132-150. PubMed ID: 37703679
[TBL] [Abstract][Full Text] [Related]
6. The efficacy and safety of direct oral anticoagulants versus vitamin K antagonists in patients with left-sided bioprosthetic heart valves and atrial fibrillation: a systematic review and meta-analysis.
Li D; Chang P; Zhang H; Bai F; Wu Q
Eur J Clin Pharmacol; 2023 Apr; 79(4):461-471. PubMed ID: 36795127
[TBL] [Abstract][Full Text] [Related]
7. Direct oral anticoagulants versus vitamin K antagonists in patients with atrial fibrillation and stage 5 chronic kidney disease under dialysis: A systematic review and meta-analysis of randomized controlled trials.
de Lucena LA; Freitas MAA; Souza AKC; Silva CHA; Watanabe JMF; Guedes FL; Almeida JB; de Oliveira RA
J Thromb Thrombolysis; 2024 Mar; 57(3):381-389. PubMed ID: 38281231
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of direct oral anticoagulants (DOACs) versus vitamin K antagonist (VKA) among patients with atrial fibrillation and hypertrophic cardiomyopathy: a systematic review and meta-analysis.
Rujirachun P; Charoenngam N; Wattanachayakul P; Winijkul A; Owattanapanich W; Ungprasert P
Acta Cardiol; 2020 Dec; 75(8):724-731. PubMed ID: 31558097
[No Abstract] [Full Text] [Related]
9. Severe Bleeding Risk of Direct Oral Anticoagulants Versus Vitamin K Antagonists for Stroke Prevention and Treatment in Patients with Atrial Fibrillation: A Systematic Review and Network Meta-Analysis.
Xu W; Lv M; Wu S; Jiang S; Zeng Z; Fang Z; Qian J; Chen M; Chen J; Zhang J
Cardiovasc Drugs Ther; 2023 Apr; 37(2):363-377. PubMed ID: 34436708
[TBL] [Abstract][Full Text] [Related]
10. Lower Major Bleeding Rates with Direct Oral Anticoagulants in Catheter Ablation of Atrial Fibrillation: an Updated Meta-analysis of Randomized Controlled Studies.
Brunetti ND; Tricarico L; Tilz RR; Heeger CH; De Gennaro L; Correale M; Ieva R; Di Biase M; Rillig A; Metzner A; Santoro F
Cardiovasc Drugs Ther; 2020 Apr; 34(2):209-214. PubMed ID: 32080786
[TBL] [Abstract][Full Text] [Related]
11. Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Cancer and Atrial Fibrillation: A Systematic Review and Meta-Analysis.
Deng Y; Tong Y; Deng Y; Zou L; Li S; Chen H
J Am Heart Assoc; 2019 Jul; 8(14):e012540. PubMed ID: 31310583
[TBL] [Abstract][Full Text] [Related]
12. Periprocedural Outcomes of Direct Oral Anticoagulants Versus Warfarin in Nonvalvular Atrial Fibrillation.
Nazha B; Pandya B; Cohen J; Zhang M; Lopes RD; Garcia DA; Sherwood MW; Spyropoulos AC
Circulation; 2018 Oct; 138(14):1402-1411. PubMed ID: 29794081
[TBL] [Abstract][Full Text] [Related]
13. Clinical profile of direct oral anticoagulants versus vitamin K anticoagulants in octogenarians with atrial fibrillation: a multicentre propensity score matched real-world cohort study.
Russo V; Attena E; Di Maio M; Mazzone C; Carbone A; Parisi V; Rago A; D'Onofrio A; Golino P; Nigro G
J Thromb Thrombolysis; 2020 Jan; 49(1):42-53. PubMed ID: 31385163
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness and Safety of Direct Oral Anticoagulants in an Asian Population with Atrial Fibrillation Undergoing Dialysis: A Population-Based Cohort Study and Meta-Analysis.
See LC; Lee HF; Chao TF; Li PR; Liu JR; Wu LS; Chang SH; Yeh YH; Kuo CT; Chan YH; Lip GYH
Cardiovasc Drugs Ther; 2021 Oct; 35(5):975-986. PubMed ID: 33211254
[TBL] [Abstract][Full Text] [Related]
15. Direct Anticoagulants Versus Vitamin K Antagonists in Patients Aged 80 Years or Older With Atrial Fibrillation in a "Real-world" Nationwide Registry: Insights From the FANTASIIA Study.
Ortiz MR; Muñiz J; Esteve-Pastor MA; Marín F; Roldán I; Cequier A; Martínez-Sellés M; Saldivar HG; Bertomeu V; Anguita M
J Cardiovasc Pharmacol Ther; 2020 Jul; 25(4):316-323. PubMed ID: 32228180
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study.
Maura G; Blotière PO; Bouillon K; Billionnet C; Ricordeau P; Alla F; Zureik M
Circulation; 2015 Sep; 132(13):1252-60. PubMed ID: 26199338
[TBL] [Abstract][Full Text] [Related]
17. Vitamin K antagonists: relative strengths and weaknesses vs. direct oral anticoagulants for stroke prevention in patients with atrial fibrillation.
Zirlik A; Bode C
J Thromb Thrombolysis; 2017 Apr; 43(3):365-379. PubMed ID: 27896543
[TBL] [Abstract][Full Text] [Related]
18. Patients with non-valvular atrial fibrillation on vitamin k antagonists or direct-acting oral anticoagulants: patients profile and long-term follow up outcomes.
Sigismondi A; Camacho-Freire SJ; León-Jiménez J; Isasti-Aizpurva G; García-Lizana MD; Morgado-García de Polavieja JI; Caro-Fernández FJ; Roa-Garrido J; Navarro-Roldán F; Díaz-Fernández JF
Arch Cardiol Mex; 2019; 89(4):382-392. PubMed ID: 31834326
[TBL] [Abstract][Full Text] [Related]
19. Direct Oral Anticoagulants versus Vitamin K Antagonists in Cirrhotic Patients with Atrial Fibrillation: Update of Systematic Review and Meta-Analysis.
Hu T; Li YH; Han WQ; Maduray K; Chen TS; Hao L; Zhong JQ
Am J Cardiovasc Drugs; 2023 Nov; 23(6):683-694. PubMed ID: 37639201
[TBL] [Abstract][Full Text] [Related]
20. Significant Benefit of Uninterrupted DOACs Versus VKA During Catheter Ablation of Atrial Fibrillation.
Romero J; Cerrud-Rodriguez RC; Alviz I; Diaz JC; Rodriguez D; Arshad S; Cerna L; Taveras J; Grupposo V; Natale A; Garcia M; Di Biase L
JACC Clin Electrophysiol; 2019 Dec; 5(12):1396-1405. PubMed ID: 31857038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
